PODD: Inverse Head And Shoulders detected on 21 Sep 2026

Insulet just reported Q2 2026 revenue of $801.7 million, up 23.5%, forming an inverse head-and-shoulders pattern at $140.60. The setup shows structure score of 11.0, volume score of 12.0, and breakout score of 10.0 for an overall score of 60.0. Current price sits 11.23% above the 52-week low, with key support at $138.28 and resistance broken above prior levels. Volume ratio of 1.37 and relative volume of 1.38 provide moderate confirmation. The pattern targets conservative upside to $148.11, representing 5.3% above current price, with win probability at 62.02%.

Insulet's International Omnipod revenue surged 35.5% in Q2 2026, demonstrating strong execution in growth markets. However, the stock has faced significant headwinds. In March 2026, Insulet disclosed its first voluntary Medical Device Correction for Omnipod 5 Pods due to a small tear in the internal tubing that delivers insulin, and on May 26, 2026, Insulet disclosed another voluntary Medical Device Correction for specific lots of Omnipod 5, Omnipod Dash, and Omnipod Insulin Management System Pods due to a manufacturing issue that could result in insulin under-delivery. Approximately 7 million Pods across product lines were affected, representing 8.5% of 2025 global production. Despite strong Q2 results, Insulet trimmed its 2026 revenue growth guidance, leading to investor caution.

A successful breakout above the inverse head-and-shoulders neckline would target the conservative measured move of $148.11, representing approximately 5.3% upside. The pattern suggests volume confirmation should exceed the 1.37x ratio already present, validating institutional accumulation. Invalidation occurs at support level $138.28; a close below this level signals the pattern has failed. With 62.02% win probability, the setup indicates slightly better-than-coin-flip odds of reaching the target. RSI at 45.19 is neutral, offering room for momentum expansion without overbought conditions limiting upside potential.

BTIG slashed its valuation multiple on Insulet from approximately 4.5x to 4x on May 26, 2026, citing continued negative investor sentiment and some risk of reputation damage or increased regulatory scrutiny from the company's second voluntary medical device correction. Goldman Sachs lowered estimates and did not fully subscribe to the reiteration of guidance. A class action lawsuit spans February 21, 2025 to May 26, 2026, with lead plaintiff deadline August 31, 2026. The sector regime is bearish (0.14 score) while stock's negative beta of -0.43 creates inverse market sensitivity. Stock trades 60.38% below 52-week highs, and elevated litigation risk could trigger negative catalysts, limiting recovery potential despite pattern setup quality.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.